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Abstract
Objective To assess the safety and efﬁcacy of lecithinized
superoxide dismutase (PC-SOD) in patients with ulcer-
ative colitis (UC).
Method PC-SOD was injected once daily at doses of
40 mg (n = 22) and 80 mg (n = 20) for a total treatment
period of 4 weeks. Efﬁcacy was assessed by UC-Disease
Activity Index (DAI) total score. All side effects were
recorded and investigated.
Results At 4 weeks, the UC-DAI total score was signif-
icantly decreased vs baseline in both the 40 mg and
80 mg groups. It was conﬁrmed that PC-SOD 80 mg
was, at least, not signiﬁcantly superior to PC-SOD
40 mg. Twenty incidences of side effects were noted in
12 (54.55%) of 22 patients in the 40 mg group, while
there were three incidences of side effects in two
(10.00%) of 20 patients in the 80 mg group. None of
these side effects was severe. Thus it was concluded that
the test drug is safe when given at daily dosages of 40 mg
and 80 mg.
Conclusion In this pilot study PC-SOD improved UC
more rapidly than previously existing drugs. A double
blind, placebo-controlled clinical trial of PC-SOD
40 mg ⁄ day is required to conﬁrm the efﬁcacy of this
agent against UC.
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Introduction
Although the pathogenesis of IBD is not fully under-
stood, it has been well documented that oxidative stress
caused by reactive oxygen species (oxygen radicals; ROS)
may trigger the onset of IBD along with contributions
from immune dysfunction and genetic and environmental
factors [1].
Superoxide dismutase (SOD), an enzyme that catal-
yses the degradation of ROS to oxygen and hydrogen
peroxide, was discovered approximately 40 years ago.
SOD prevents oxidation in cells of many tissues such as
vascular endothelial cells exposed to ROS. SOD is
presumably the most potent anti-ROS and was early
thought potentially a dream drug. However, as SOD
does not bind to cellular membranes and is rapidly
excreted from the kidney, it has not been practically
used so far [2]. In this regard, several attempts have
been made to prepare practical SOD formulations.
Although hybrid chimeric SOD (SOD2 ⁄ 3) and recom-
binant human SOD (h-SOD) improved pharmacokinet-
ics proﬁles and ameliorated symptoms in animal studies
[3], to date h-SOD has not shown beneﬁcial effects in
patients [4].
PC-SOD is a lecithinized SOD in which four phospha-
tidylcholine (PC)-derivative molecules are covalently
bound to each SOD dimer. PC-SOD has a high afﬁnity
to cellular membranes [5] and efﬁciently scavenges super-
oxide anion (O
2)) produced at affected tissues [6].
Furthermore, PC-SOD has a long half-life in serum [7],
maintainsenzymaticactivityfor6 hafterinjection[8],and
exhibited beneﬁcial effects in animal models of various
diseases in which ROS involvement is implicated [7–12].
Thus PC-SOD might be expected to elicit beneﬁcial
effects in clinical studies against ROS-mediated diseases
such as inﬂammatory bowel disease and the like.
Method
Prior to participation in the study, we obtained agree-
ment and received written informed consent from
all patients in accordance with the International
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Subjects enrolled in the present clinical trial were
patients who were diagnosed as having UC based on
American College of Gastroenterology ‘Ulcerative coli-
tis practice guideline in adults’ [13]. The test drug
used was a preparation for intravenous injection con-
taining 40 mg of PC-SOD in one vial (freeze-dried
preparation). The test drug was intravenously injected
at a dose of 40 or 80 mg by drip infusion for
approximately 60 min. The drug was injected once
daily initially for 14 days as inpatient treatment
followed by twice weekly for another 2 weeks as
outpatient treatment. Previously prescribed immuno-
suppressants (azathioprine, mercaptopurine), other anti-
UC agents (mesalazine, salazosulfapyridine), and steroid
preparations were concomitantly allowed without any
changes of their doses and administration routes and
schedules. However, concomitant cyclosporine and
centrifugal leukocyte aphaeresis therapy were prohib-
ited. Although all participants were followed until
endoscopy was carried out at 1 month following
injection, in this study follow-up could not be contin-
ued thereafter because other therapies were subse-
quently given to most patients.
Efﬁcacy assessment of the test drug was conducted
based on four items (stool frequency, bloody stool,
mucosal ﬁndings, and doctors’ global assessment) in
Ulcerative Colitis-Disease Activity Index (UC-DAI) [14].
The UC-DAI total score was calculated at baseline and
week 4 or at the withdrawal visit for patients who early
discontinued. Patients whose UC-DAI total score at
4 weeks was ‡ 2 points lower than the baseline level were
deﬁned as ‘improved.’
Safety assessment of the test drug was conducted
based on incidence rates of side effects and abnormal
clinical parameters at baseline and at 1, 2, and 4 weeks of
treatment.
Results
Baseline characteristics
Of 42 patients enrolled, 22 and 20 patients were
randomly assigned to receive PC-SOD 40 and 80 mg,
respectively. The mean disease duration (± SD) was
59.1 ± 48.0 and 78.8 ± 74.5 months, respectively.
Baseline characteristics such as age, body weight, sex,
and disease duration were not signiﬁcantly different in
the two groups. In all, three patients who withdrew
from the study were excluded from the efﬁcacy assess-
ment — one in the 40 mg group and two in the 80 mg
group.
Efﬁcacy
As shown in Fig. 1, UC-DAI total score in most patients
was reduced in both the 40 mg and 80 mg groups at
4 weeks vs baseline. ‘Improved’ patients numbered 17
(81%) and 11 (61%) in the 40 mg and 80 mg groups,
respectively (inserted table in Fig. 1). Mean (SD) UC-
DAI total scores at 4 weeks in the 40 mg (4.1 ± 2.4) and
80 mg (5.6 ± 3.0) groups were signiﬁcantly lower than
their average baseline levels (40 mg group, 7.9 ± 1.9;
80 mg group, 8.5 ± 1.4), indicating that PC-SOD
improved UC.
Safety
Among the 42 patients, there were 23 incidences in 14
patients (33.3%) of side effects possibly related to taking
the test drug. In the 40 mg group there were 20 patients
of side effects appearing in 12 (54.5%)of 22 patients
assessed, while in the 80 mg group three patients of side
effects were recorded in two (10.0%)of 20 patients
assessed. Side effects included nausea (2.4%), fever
(2.4%), headache (2.4%), malaise (2.4%), and low back
pain (2.4%). None of the side effects was severe and the
incidence of side effects was not related to the dose of
PC-SOD. Abnormal laboratory tests included increased
WBC (7.1%), elevated c-GTP (4.8%), and positive urinary
protein (4.8%).
Discussion
Reactive oxygen species are produced as a by-product of
normal oxygen metabolism and degraded by defense
mechanisms including SOD. Overproduction of ROS
exceeding the degradation capacity of such defense
mechanisms is implicated in the pathogenesis of inﬂam-
matory diseases such as IBD, neurodegenerative diseases,
cardiovascular diseases, and cancer. Although SOD is
anti-oxidant, overexpression of this enzyme conversely
produces ROS. Thus a balance between ROS and SOD is
important [2].
In this study PC-SOD given at a daily dosage of 40
and 80 mg signiﬁcantly lowered UC-DAI total score, the
major assessment item in UC, at 4 weeks vs baseline.
There was no signiﬁcant difference between the two
treatment groups. Furthermore, ‘noninferiority’ analysis
conﬁrmed that the 80 mg group was, at least, not
signiﬁcantly superior to the 40 mg group (data not
shown). Recently, PC-SOD was reported to activate
SOD activity linearly in men at doses from 20 to 80 mg
in a clinical study to investigate pharmacokinetics as well
as safety and tolerability of PC-SOD in men. Particularly,
PC-SOD increased SOD activity over baseline levels from
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the same doses as were used in the present study [15].
Thus beneﬁcial effects of PC-SOD against IBD were
strongly suggested by improvement of half-life and
afﬁnity to the cell membrane [5,6].
In this study follow-up could not be continued after
1 month because other therapies were subsequently given
to most patients. Furthermore, their therapies were not
restricted. Thus although a question of interest it could
not be determined whether remissions occurred in
subjects following discontinuation of test therapy.
Although the incidence of side effects was higher in
the 40 mg group than in the 80 mg group, none of the
side effects was severe. As efﬁcacy was similar in the two
groups and side effects were not dose related, the
optimum dose of the test drug was concluded 40 mg.
Although efﬁcacy of the test drug was assessed at
4 weeks in the present study, many previously existing
drugs were clinically tried over an 8-week period. As
PC-SOD elicited signiﬁcant improvements of UC at
4 weeks in the present study, the beneﬁcial effects of
PC-SOD might appear earlier than those of other drugs
such as mesalazine and the like. A double blind,
placebo-controlled clinical trial of PC-SOD 40 mg ⁄ day
is required to conﬁrm the efﬁcacy of PC-SOD against
UC.
References
1 Rezaie A, Parker RD, Rezaie A. Oxidative stress and
pathogenesis of inﬂammatory bowel disease: an epiphenom-
enon or the cause? Dig Dis Sci 2007; 52: 2015–21.
2 McCord JM, Edeas MA. SOD, oxidative stress and human
pathologies: a brief history and a future vision. Biomed
Pharmacother 2005; 59: 139–42.
3 Hernandez-Saavedra D, Zhou H, McCord JM. Anti-inﬂam-
matory properties of a chimeric recombinant superoxide
dismutase:SOD2 ⁄ 3.BiomedPharmacother2005;59:204–8.
4 Flaherty JT, Pitt B, Gruber JW et al. Recombinant human
superoxide dismutase (h-SOD) fails to improve recovery of
ventricular function in patients undergoing coronary angio-
plasty for acute myocardial infarction. Circulation 1994; 89:
1982–91.
5 Igarashi R, Hoshino J, Ochiai A et al. Lecithinized super-
oxide dismutase enhances its pharmacologic potency by
increasing its cell membrane afﬁnity. J Pharmacol Exp Ther
1994; 271: 1672–7.
6 Igarashi R, Hoshino J, Takenaga M et al. Lecithinization of
superoxide dismutase potentiates its protective effect against
0(0%)
17(81)% 11(61%)
6(33%) 4(19%)
1(6%)
40 mg 80 mg
Mean ± S. D.
12
10
8
6
4
2
0
12
10
8
6
4
2
0
Before After
ΔΔ
Before After
Improved
Unchanged
Aggravated
Improvement by 2 or more
regarded as “improved” 7.9 ± 1.9
4.1 ± 2.4
–3.8 ± 2.5
8.5 ± 1.4
5.6 ± 3.0
–2.9 ± 2.6
Figure 1 Improving effects of PC-SOD on UC-DAI total score in patients with active ulcerative colitis. UC-DAI total score in
individual subjects at baseline and after treatment with PC-SOD 40 mg (left graph) and 80 mg (right) is connected by lines. Ordinate:
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in the 40 mg group at baseline (7.9 ± 1.9) was signiﬁcantly reduced by 3.8 ± 2.5 and that in the 80 mg group (8.5 ± 1.4) signiﬁcantly
lowered by 2.9 ± 2.6. The inserted table indicates the rate of patients improved, unchanged, and aggravated following treatment with
PC-SOD. ‘Improved’ was deﬁned as subjects whose UC-DAI total score after treatment was reduced by ‡ 2 points.
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